Skip to main content

Table 1 Primary enzyme assay hits

From: Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction

Position

NicA2 variant

Fold improvement over wt

 

wt

1

 

Δ50

0.7

91

Δ50R91A

3.8

R91Q

3.3

Δ50R91Q

3.1

Δ50R91F

2.7

Δ50R91G

2.5

Δ50R91T

2.4

Δ50R91L

2.4

Δ50R91S

2.1

104

F104R

6.4

F104K

5.9

F104I

3.8

F104 L

3.5

F104S

3.2

F104 T

2.3

106

G106S

3.9

G106A

3.8

107

A107R

19.0

Δ50A107R

17.3

A107K

6.7

A107T

5.9

A107G

4.9

A107H

4.8

A107P

3.5

217

Δ50L217Q

2.8

Δ50L217G

2.3

Δ50L217E

2.0

249

E249W

5.5

E249D

2.7

250

T250G

4.7

Δ50T250L

3.5

340

Δ50K340P

2.1

355

F355H

13.4

F355K

4.6

F355C

2.6

366

Δ50Q366K

4.9

Δ50Q366E

3.2

Q366K

3.1

Δ50Q366V

2.4

Δ50Q366L

2.2

381

Δ50T381P

5.5

Δ50T381I

5.4

Δ50T381V

4.9

Δ50T381Q

4.3

Δ50T381N

2.7

Δ50T381L

2.4

Δ50T381M

2.1

426

A426Q

5.2

A426W

4.9

427

Δ50W427S

3.3

Δ50W427E

3.1

Δ50W427Q

3.0

Δ50W427M

2.8

462

Δ50N462L

6.5

Δ50N462Y

5.7

Δ50N462S

4.2

N462Y

3.2

Δ50N462F

3.1

Δ50N462G

3.0

Δ50N462E

2.6

Δ50N462A

2.2

463

Δ50I463F

3.7

Δ50I463Y

3.5

  1. The 58 single amino acid variants identified at 15 unique positions within the set of 22 active site residues (listed in Experimental Procedures) with enzymatic activity at least 2-fold greater than wt NicA2 in the Amplex Red primary screening assay
Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us